So far this year, Amplion has tracked 67 Seed and Series A investments into early-stage biotechs - down from 92 or a 27% decrease during the same period last year. That said, the biotech sector continues to witness rapid advancements, with numerous early-stage companies securing substantial investments to fuel their groundbreaking research and development efforts. [...]The post Seed and Series A Biotech Funding: 2023 appeared first on Amplion.
Amplion is an Oregon-based AI-powered biomarker intelligence platform to accelerate the precision medicine approach for industries such as pharmaceutical and life sciences.